On Friday, the UN Security Council gave up on issuing a statement calling for an end to violence in the Ethiopian Tigray region, due to opposition from China and Russia, diplomats told AFP.
After the council negotiated a draft resolution over two days, a diplomat who requested anonymity said, “There will be no” statement.
A second diplomatic source, who asked not to be named, confirmed that “there is no consensus,” saying, “There are no plans to go further.”
A third diplomat clarified that China objected to the drafting of the statement, demanding that the phrase “violence in Tigray” be removed. However, the diplomat said that this request was rejected by Western countries in the council, including Ireland, which drafted the document.
Russia supported China’s position in its objection to the text. Since the start of the violence in Tigray, these two countries have said that the issue is a domestic issue for Ethiopia and not that of the United Nations.
Diplomats said China and Russia wanted the draft to focus only on the dire humanitarian situation in the region.
The last UN Security Council session on Tigray was held on 2 February to demand that more humanitarian aid be allowed into the area. On that day, China and the African members of the council (South Africa, Niger and Tunisia) opposed the issuance of a statement by the council.
Earlier Friday, Human Rights Watch said that Eritrean forces killed hundreds of children and civilians in November in the Tigray massacre.
This was the second major report issued in the past week about violations alleged by the Eritrean army in the town of Axum, which is included in the United Nations Educational, Cultural and Scientific Organization (UNESCO) World Heritage List.
An Amnesty International investigation into the same incidents spoke of the “systematic killing of hundreds of civilians in cold blood” by the Eritrean army.
Hani Aref, Professor and Head of the Department of Neurology, Faculty of Medicine, Ain Shams University, revealed new details about the treatment of the child Rayan from spinal muscular atrophy with the most expensive injection in the world, whose price reaches 34 million pounds. Aref stressed in exclusive statements to “Echo of the Country” website that finding a treatment for spinal muscular atrophy is of special importance because this disease in most cases leads to death due to its weakening of the breathing muscles. He added that the infection with this disease occurs as a result of a genetic deficiency that results from a specific protein deficiency, explaining that fortunately some gene therapies have begun to appear and contribute to treating the affected gene about 5 or four years ago, and these treatments can open or close the gene and modify its mutations. And it started to give positive results.
And about the way the treatment works, Aref said that he enters the DNA of the pomegranate and begins to treat the deficient protein that originally caused the disease, and if the child gets it early in the disease, this helps him to live normally in the future. Aref pointed out that this type of gene therapy is the latest trend, and it is implemented with very high technology, so its cost reaches millions, pointing out that the price of the treatment is expected to decrease with time, and that by analogy with that, the analysis of genes when it appeared at its inception cost 100 million dollars That was 20 years ago, and with time the price decreased, bringing the price of the analysis to $ 1,000 only. For her part, Dr. Najia Ali Fahmy, Director of the Muscle and Neurotherapy Unit at the Faculty of Medicine, Ain Shams University, said that treating a child from spinal muscular atrophy disease is something that happens for the first time in Egypt with the latest treatment in the world.
She explained that during this treatment, a factory gene is transferred to take the role and functions of the gene affected by the genetic mutation, and this gene enters the body through a virus that carries it. Najia said that she considers the treatment of the child Rayan a promising start for treating Egyptian children who suffer from this disease, noting that the high rate of inbreeding in Egypt leads to the emergence of many cases of it, despite it being a rare disease in the world. She added: “Treating the child Rillen opens the door for officials and society to treat the rest of the children with this disease, especially since there are other treatments that are not related to the manufacture of a new gene, but rather to modify it, and there are two other treatments that are less expensive than gene therapy and are internationally approved, and we must start negotiating its entry into Egypt and saving it.” Hundreds of children.